Shawn He
Chief Scientific Officer JW Therapeutics
Seminars
Thursday 17th September 2026
Demonstrating Clinical Success in CD19/CD20 Dual CAR Innovation to Enhance Clinical Impact
11:25 am
- Detailing the development rationale behind dual CAR design to address resistance challenges and broaden therapeutic applicability
- Showcasing positive IIT clinical trial data for JW Therapeutics’ JWCAR201
- Illustrating the potential of dual CAR-T platforms to advance treatment options across oncology and autoimmunity
